Comparative Pharmacology
Head-to-head clinical analysis: ADENOSINE versus CORVERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSINE versus CORVERT.
ADENOSINE vs CORVERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts as a non-selective agonist at adenosine A1, A2A, A2B, and A3 receptors. It slows atrioventricular (AV) conduction through activation of A1 receptors, which increases potassium efflux and reduces calcium influx, hyperpolarizing nodal cells and prolonging refractoriness. This terminates reentrant supraventricular tachyarrhythmias involving the AV node.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Paroxysmal supraventricular tachycardia: 6 mg rapid IV bolus over 1-2 seconds; if no conversion in 1-2 minutes, give 12 mg rapid IV bolus; may repeat 12 mg once if necessary. Maximum single dose: 12 mg. Also used for cardiac stress testing: 140 mcg/kg/min IV infusion over 6 minutes, total dose 0.84 mg/kg.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
None Documented
None Documented
Clinical Note
moderateCarbamazepine + Adenosine
"The risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine."
Clinical Note
moderateTheophylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline."
Clinical Note
moderateDyphylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline."
Clinical Note
moderateAminophylline + Adenosine
Terminal elimination half-life <10 seconds (rapidly cleared from plasma by cellular uptake and metabolism); clinical context: transient effects require continuous IV infusion for sustained action.
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
Hepatic metabolism (primarily via adenosine deaminase and adenosine kinase) to inosine and AMP; renal excretion of metabolites accounts for <10% of elimination.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline."